Genetics of Lymphatic Anomalies from the Center for Applied Genetics (CAG) at CHOP
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA529275 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Genetics of Lymphatic Anomalies from the Center for Applied Genetics (CAG) at CHOP
| PRJNA529276 | ENA
Project description:<p>Lymphatic anomaly, a rare and devastating disease spectrum of mostly unknown etiologies, is characterized by diffuse or multicentric proliferation of dilated lymphatic vessels, and includes a variety of diagnoses: lymphangiectasia, central conducting lymphatic anomaly, generalized lymphatic anomaly, kaposiform lymphangiomatosis, and Gorham Stout disease. Currently, most treatments are considered palliative; lymphatic anomalies are often chronic debilitating conditions that require multiple yearly outpatient visits and hospital admissions for procedures that ameliorate symptoms, but do not correct the underlying cause. Identifying the causal genes will be hugely informative for our understanding of diseases. This will also allow for the development of affordable and successful diagnostic tests and therapies in keeping with "precision medicine" implementation.</p>
| phs001802 | dbGaP
Project description: Not available
| S-EPMC3938256 | biostudies-literature
Project description:eMERGE: Genetics of Complex Pediatric Disorders (GCPD), CAG-CHOP Biobank
| PRJNA327667 | ENA
Project description:Genetics of Congenital Anomalies of the Kidney and Urinary Tract
| PRJNA507683 | ENA
Project description:Genetics of Congenital Anomalies of the Kidney and Urinary Tract
| PRJNA507684 | ENA
Project description:The lymphatic vascular system maintains tissue fluid homeostasis, helps mediate afferent immune responses and promotes cancer metastasis. MicroRNAs (miRNAs) have recently emerged as key and potent regulators of the genome that control virtually all aspects of cell and organism biology. Surprisingly, the physiological importance and functional activities of miRNAs in the lymphatic vascular system have not been explored. To address this, we first defined the in vitro miRNA expression profiles of primary human lymphatic endothelial cells (LECs) and blood vascular endothelial cells (BVECs). Comparative analysis of these profiles identified 4 BVEC-signature and 2 LEC-signature miRNAs. Further expression analysis by quantitative real-time PCR analysis and by in situ hybridization (ISH) studies confirmed these vascular lineage-specific expression patterns in vivo. Functional characterization of the BVEC-signature miRNA, miR-31, identified a novel BVEC-specific post-transcriptional regulatory mechanism that inhibits lymphatic-specific transcription programs in vitro and lymphatic vascular development during Xenopus embryogenesis. These effects are, in part, mediated via direct post-transcriptional repression of PROX1, a master regulator of lymphatic lineage-specific differentiation. Together, these findings indicate that miR-31, and miRNAs in general, are potent regulators of vascular lineage-specific differentiation and development. 500,000 LECs were transfected with 2 µM Pre-miR-31 or Pre-miR-Neg molecules in biological duplicate and total RNA isolated using the mirVana isolation kit 48 hours post-transfection. The transcriptome profiles of these cells were defined using the Applied Biosystems Human Genome Survey Microarray v2.0 as described. Briefly, dioxigenin-UTP-labeled cRNA was generated from 1.5 µg of total RNA using the NanoAmp RT-IVT Labeling Kit (Applied Biosystems). 20 µg cRNA were fragmented and hybridized to the microarrays using the Applied Biosystems Chemiluminescence Detection Kit. Signal detection, image acquisition and initial analyses were performed using the Applied Biosystems 1700 Chemiluminescent Microarray Analyzer. Raw data were normalized using Quantile normalization available from R/Bioconductor. Present calls were defined based on average signal-to-noise ratios (S/N ratio) >3 and quality (error) values <5,00025. Feature signal intensities were converted to log2 values. miR-31-repressed genes were identified based on present calls in both Pre-miR-Neg arrays, log2(Pre31/PreNeg) �-0.59 and p-values <0.05, while miR-31-induced genes were present in both Pre-miR-31 arrays, had log2(Pre31/PreNeg) �0.59 and p-values <0.05. P-values were calculated using empirical Bayes statistics for differential expression.
2010-06-16 | E-GEOD-16908 | biostudies-arrayexpress
Project description:Complex lymphatic anomalies (CLAs) are sporadically occurring diseases caused by the maldevelopment of lymphatic vessels. We and others recently reported that somatic activating mutations in KRAS can cause CLAs. However, the mechanisms by which activating KRAS mutations cause CLAs are poorly understood. Here we show that KRASG12D expression in lymphatic endothelial cells (LECs) during embryonic development impairs the formation of lymphovenous valves and causes the enlargement of lymphatic vessels. We demonstrate that KRASG12D expression in primary human LECs induces cell spindling, proliferation, and migration. It also increases AKT and ERK1/2 phosphorylation and decreases the expression of genes that regulate lymphatic vessel maturation. We show that MEK1/2 inhibition with the FDA-approved drug trametinib suppresses KRASG12D-induced morphological changes, proliferation, and migration. Trametinib also decreases ERK1/2 phosphorylation and increases the expression of genes that regulate the maturation of lymphatic vessels. We also show that trametinib and Cre-mediated expression of a dominant-negative form of MEK1 (Map2k1K97M) suppresses KRASG12D-induced lymphatic vessel hyperplasia in embryos. Last, we demonstrate that conditional knockout of wild-type Kras in LECs does not affect the formation or function of lymphatic vessels. Together, our data indicate that KRAS/MAPK signaling must be tightly regulated during embryonic development for the proper development of lymphatic vessels and further support the testing of MEK1/2 inhibitors for treating CLAs.
2023-09-25 | GSE239737 | GEO
Project description:A "Cartes d'Identite des Tumeurs" (CIT) project from the french Ligue Nationale Contre le Cancer (http://cit.ligue-cancer.net). 53 samples hybridized on Affymetrix HG-U133A GeneChips arrays, for 53 patients with diffuse large B-cell lymphoma (DLBCL); patients are treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or Ritxumab (R)-CHOP in the Groupe dB^REtude des Lymphomes de lB^RAdulte (GELA) clinical centers.
2008-06-01 | E-TABM-346 | biostudies-arrayexpress